...
首页> 外文期刊>Therapeutic Drug Monitoring >Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.
【24h】

Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.

机译:在患有严重抑郁症的患者中,接受曲美唑诱导的文拉法辛血清浓度升高后发生严重震颤。

获取原文
获取原文并翻译 | 示例
           

摘要

: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 due to a genetic deficit and (2) inhibition of CYP2C9 by cotrimoxazole.
机译::我们描述了一位女性患者,该患者是细胞色素P450同工酶(CYP)2D6的广泛代谢者和CYP2C19的中间代谢者(基因型:CYP2C19 * 1 / * 2)。她表现出高浓度的文拉法辛和O-去甲基文拉法辛,并在用考特莫唑(磺胺甲唑/甲氧苄氨嘧啶)进行喜剧表演后出现严重的震颤。文拉法辛主要通过O-和N-去甲基化代谢。 O-去甲基化由高度多态的CYP2D6催化,N-去甲基化由几种酶CYP2C19,CYP2C9和CYP3A4催化。观察到的总体药代动力学作用很可能是由于(1)由于遗传缺陷导致CYP2C19的表达减少和(2)受cotrimoxazole抑制CYP2C9导致文拉法辛的N-去甲基化降低的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号